ArticleAnnals of translational medicine2022

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.

Guanghui Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.